In a significant move aimed at improving accessibility and competitiveness in the Indian market, Novo Nordisk has announced substantial price reductions for its popular semaglutide-based therapies, Ozempic and Wegovy. This decision comes shortly after the entry of lower-cost generic alternatives, which have disrupted the pricing landscape following the patent expiry of semaglutide in India on March 20. The most notable revision is seen in the starting dose (0.25 mg) monthly pen for both Ozempic and Wegovy, which has now been priced at Rs 5,660.
This reflects a steep reduction of 36% for Ozempic and 48% for Wegovy. By aligning the prices of both brands at this entry-level dose, Novo Nordisk appears to be responding strategically to increased competition while attempting to maintain its market presence. Beyond the starting dose, the company has implemented broader price cuts across its…
